CBER official overturns Replimune melanoma drug rejection; AbbVie reports phase 3 success in multiple myeloma
read at raps ↗RegulatoryNeutral
A CBER regulator has reversed a prior decision to reject Replimune's experimental melanoma therapy, allowing the program to move forward.
AbbVie announced that its multiple myeloma candidate achieved a positive outcome in a phase 3 trial, signaling a potential new treatment option for the disease.
The regulatory reversal and the trial success could influence investor sentiment and development strategies across the oncology sector.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drug”
read at raps ↗63 words · retrieved Sep 3
comments(0)
5-min edit window · permanent after that